Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137494 | Leukemia Research | 2012 | 4 Pages |
Abstract
We studied a retrospective cohort of 282 higher-risk MDS treated with azacitidine, including 32 patients who concomitantly received an ESA for a median of 5.8 months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached HI-E (p = 0.07); 48% and 20% achieved transfusion independence (p = 0.01). Median OS was 19.6 months in the ESA and 11.9 months in the no-ESA groups (p = 0.04). Addition of an ESA significantly improved OS (p = 0.03) independently of azacitidine schedule and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should be studied prospectively.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
R. Itzykson, S. Thépot, O. Beyne-Rauzy, S. Ame, F. Isnard, F. Dreyfus, C. Salanoubat, A.L. Taksin, Y. Chelgoum, C. Berthon, J.V. Malfuson, L. Legros, N. Vey, P. Turlure, C. Gardin, S. Boehrer, L. Ades, P. Fenaux,